Physician profile
John Panos
NPI 1407887128
$5,958.36
in general payments reported to CMS, 2019-2025
21 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.92 · 2021: $674 · 2022: $1,280 · 2023: $1,209 · 2024: $1,335 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,900 · Education: $83.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,900.35 |
| Education | $83.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,055.46 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $951.70 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $836.80 | 2022-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $778.12 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $467.44 | 2021-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $415.45 | 2021-2025 | Rayaldee |
| Vifor Pharma, INC. | $256.71 | 2020-2025 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $227.45 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $146.98 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.91 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $140.64 | 2021-2024 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $121.07 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $89.36 | 2021-2024 | Ultomiris |
| Novo Nordisk INC | $78.56 | 2022-2025 | Wegovy, Ozempic |
| Aurinia Pharma U.S., INC. | $69.33 | 2021-2023 | Lupkynis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $50.91 | 2021 | |
| Ani Pharmaceuticals, INC. | $28.75 | 2025 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $25.91 | 2025 | Empaveli |
| Ardelyx, INC. | $25.67 | 2025 | Ibsrela |
| Esperion Therapeutics, INC. | $24.32 | 2024 | Nexletol |
| Fresenius USA Marketing, INC. | $20.82 | 2025 | Velphoro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Panos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.